Preliminary study on double-dose icotinib successfully treated leptomeningeal metastasis in lung adenocarcinoma patient with EGFR gene sensitive mutation

doi:10.3969/j.issn.1672-6731.2021.11.013

Abstract

Abstract:

Objective To report the diagnosis and treatment of a patient with meningeal metastases from lung adenocarcinoma, and explore the significance of cerebrospinal fluid (CSF) gene detection for clinical treatment and the efficacy and safety of double-dose icotinib in the treatment of meningeal metastases from lung adenocarcinoma with EGFR gene sensitive mutation. Methods and Results A 56-year-old female patient with meningeal metastasis from lung adenocarcinoma was examined for CSF and blood double-sample genes. The CSF had an exon 19 deletion mutation in the EGFR gene, and no sensitive mutations were found in blood sample. Oral icotinib hydrochloride 250 mg/time (3 times/d), and chest CT and head MRI enhanced scans were re-examined every 8 weeks, suggesting that the lung tumor was significantly reduced, and the degree of jumbo meningeal enhancement was lessened than before. Right lateral ventricle-peritoneal shunt was performed to effectively reduce intracranila pressure (ICP) and relieve clinical symptoms. Up to September 21, 2019, patient had been taking double doses of icotinib for 589 d, and her condition was stable. The main adverse drug reaction is rash. She is still taking medication and is being followed up. Conclusions For patients with meningeal metastases from lung adenocarcinoma, CSF gene detection of EGFR gene sensitive mutation can guide clinical development of treatment strategies. Double-dose icotinib is effective in treating meningeal metastases from lung adenocarcinoma with EGFR gene sensitive mutation, and is well tolerated and safe.

Key words: Carcinoma, non-small-cell lung, Neoplasm metastasis, Meninges, Receptor, epidermal growth factor, Cerebrospinal fluid, Genes, Mutation, Drug therapy

摘要：

目的报告1例肺腺癌柔脑膜转移患者的诊断与治疗经过，探讨脑脊液基因检测对临床治疗的指导意义，以及双倍剂量埃克替尼治疗伴EGFR基因敏感突变的肺腺癌柔脑膜转移的疗效与安全性。方法与结果 初诊女性肺腺癌柔脑膜转移患者，56岁。脑脊液及血液双标本基因检测显示，脑脊液EGFR基因外显子19缺失突变、血液标本呈阴性。予埃克替尼250 mg/次（3次/d）口服，每间隔8周复查胸部CT和头部增强MRI，肺部肿瘤灶呈渐进性缩小，柔脑膜强化程度减轻。通过右侧侧脑室-腹腔分流术降低颅内压、缓解症状与体征。截至2019年9月21日已治疗589天，病情稳定，主要药物不良反应为皮疹，仍继续服药并随访。结论对于肺腺癌柔脑膜转移患者，脑脊液基因检测EGFR基因敏感突变状态可指导临床制定治疗策略；双倍剂量埃克替尼治疗伴EGFR基因敏感突变的肺腺癌柔脑膜转移疗效确切，耐受性和安全性良好。

关键词: 癌,非小细胞肺, 肿瘤转移, 脑膜, 受体,表皮生长因子, 脑脊髓液, 基因, 突变, 药物疗法

LIU Mei, MU Ning, MA Chun-hua, LI Jin-duo, LI Lin, JIANG Rong. Preliminary study on double-dose icotinib successfully treated leptomeningeal metastasis in lung adenocarcinoma patient with EGFR gene sensitive mutation[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(11): 1001-1006.

刘梅, 穆宁, 马春华, 李金铎, 李林, 姜镕. 双倍剂量埃克替尼治疗EGFR基因敏感突变肺腺癌柔脑膜转移疗效初探[J]. 中国现代神经疾病杂志, 2021, 21(11): 1001-1006.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2021.11.013

https://journal11.magtechjournal.com/cjcnn/EN/Y2021/V21/I11/1001

References

[1] Jiang BY, Li YS, Guo WB, Zhang XC, Chen ZH, Su J, Zhong WZ, Yang XN, Yang JJ, Shao Y, Huang B, Liu YH, Zhou Q, Tu HY, Chen HJ, Wang Z, Xu CR, Wang BC, Wu SY, Gao CY, Zhang X, Wu YL. Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerbrospinal fluid circulating tumor cells[J]. Clin Cancer Res, 2017, 23:5480-5488.
[2] Ma CH, Jiang R, Li JD, Wang B, Sun LW, Lü Y. Research progress of lung cancer with leptomeningeal metastasis[J]. Zhongguo Fei Ai Za Zhi, 2014, 17:695-700.[马春华, 姜镕, 李金铎, 王斌, 孙立伟, 吕远. 肺癌柔脑膜转移的研究进展[J].中国肺癌杂志, 2014, 17:695-700.]
[3] Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas[J]. J Thorac Oncol, 2014, 9:195-199.
[4] Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. EGFR mutation status on brain metastases from non-small cell lung cancer[J]. Lung Cancer, 2016, 96:101-107.
[5] Wu YL, Liu XQ, Mao WM, Wang QM, Feng JF, Liu AW, Hu YP, Chen HQ, Yang XN, Chuai SK, Lu S, Chen M, Xu L, Huang B, Yang JJ, Zhou JY, Dong XR, Xu SD, Cui JW, Yan H, Wang CL, Zhou CC, Wang LH, Jiang BY, Zhang L, Song QB, Chen KN, Zhao Q, Mu JW, Liao ML, Chen XY, Wang J, Zhang L, Zhang XC, Hu CP, Zhu GY, Zhang ZF, Wang LP, Zhou DX, Guan ZZ, Cheng Y, Huang C, Zhou QH, Chen LK, Fu XL, Song Y, Chen Y, Li Q, Zhong WZ, Sun H, Fan Y, Wu G, Chen C, Liu YP, Zhou Q, Cai XY, Han BH, Tu HY, Wang Q, Zhao MF, Yang F, Wu L, Hu J, Chang JH, Huang YC, Ma ZY, Li JL, Qiao GB. Diagnosis and treatment consensus of brain and leptomeningeal metastasis from lung cancer[J]. Xun Zheng Yi Xue, 2018, 18:193-200.[吴一龙, 刘晓晴, 毛伟敏, 王启鸣, 冯继锋, 刘安文, 胡艳萍, 陈海泉, 杨学宁, 揣少坤, 陆舜, 陈明,许林, 黄飚, 杨衿记, 周建英, 董晓荣, 徐世东, 崔久嵬, 阎海,王长利, 周彩存, 王绿化, 江本元, 张力, 宋启斌, 陈克能, 赵琼, 牟巨伟, 廖美琳, 陈晓媛, 王洁, 张力, 张绪超, 胡成平, 朱广迎, 张真发, 王丽萍, 周德祥, 管忠震, 程颖, 黄诚, 周清华,陈丽昆, 傅小龙, 宋勇, 陈元, 李强, 钟文昭, 孙浩, 范云, 伍钢,陈椿, 刘云鹏, 周清, 蔡修宇, 韩宝惠, 涂海燕, 王群, 赵明芳, 杨帆, 邬麟, 胡洁, 常建华, 黄云超, 马智勇, 李峻岭, 乔贵宾.肺癌脑(膜)转移诊断治疗共识[J]. 循证医学, 2018, 18:193-200.]
[6] Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer[J]. J Neurooncol, 2010, 99:283-286.
[7] Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S. A phase Ⅰ trial of high dose gefitinib for patients with leptomeningeal metastases from non -smallcell lung cancer[J]. Oncotarget, 2015, 6:4527-4536.
[8] How J, Mann J, Laczniak AN, Baggstrom MQ. Pulsatile erlotinib in EGFR-positive non-small-cell lung cancer patients with leptomeningealand brain metastases:review of the literature[J]. Clin Lung Cancer, 2017, 18:354-363.
[9] Ding J, Dai X, Meng XY, Wang G. Research progress of response evaluation criteria in solid tumors[J]. Zhongguo Zhong Liu Lin Chuang Yu Kang Fu, 2015, 22:1150-1152.[丁婕, 戴旭,孟宪运, 王冠. 实体瘤疗效评价标准的研究进展[J]. 中国肿瘤临床与康复, 2015, 22:1150-1152.]
[10] Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancerpatients with leptomeningeal carcinomatosis[J]. J Thorac Oncol, 2015, 10: 1754-1761.
[11] Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non -small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI[J]. Lung Cancer, 2009, 65:80-84.
[12] Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lungcancer[J]. J Thorac Oncol, 2013, 8:1069-1074.
[13] Fan Y, Zhu X, Xu Y, Lu X, Xu Y, Wang M, Xu H, Ding J, Ye X, Fang L, Huang Z, Gong L, Lu H, Mao W, Hu M. Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer[J]. Clin Cancer Res, 2018, 24:209-216.
[14] Li YS, Jiang BY, Yang JJ, Zhang XC, Zhang Z, Ye JY, Zhong WZ, Tu HY, Chen HJ, Wang Z, Xu CR, Wang BC, Du HJ, Chuai S, Han-Zhang H, Su J, Zhou Q, Yang XN, Guo WB, Yan HH, Liu YH, Yan LX, Huang B, Zheng MM, Wu YL. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR -mutant non -small-cell lung cancer:a new medium of liquid biopsy[J]. Ann Oncol, 2018, 29:945-952.
[15] Tan FL, Zhang L, Zhao Q, Liu DY, Hu YY, Liu Y, Ding LM, Hu B, Wang YX. Pharmacology and clinical evaluation of icotinib hydrochloride[J]. Zhongguo Xin Yao Za Zhi, 2009, 18:1691-1694.[谭芬来, 张力, 赵琼, 刘东阳, 胡云雁, 刘勇, 丁列明, 胡蓓, 王印祥. 国家一类新药盐酸埃克替尼的药理与临床评价[J]. 中国新药杂志, 2009, 18:1691-1694.]
[16] Li X, Qin N, Wang JH, Yang XJ, Zhang XY, Lü JL, Wu YH, Zhang H, Nong JY, Zhang Q, Zhang SC. Clinical observation of icotinib hydrochloride for advanced non-small cell lung cancer patients with EGFR status identified[J]. Zhongguo Fei Ai Za Zhi, 2015, 18:734-739.[李曦, 秦娜, 王敬慧, 杨新杰, 张新勇,吕嘉林, 吴羽华, 张卉, 农靖颖, 张权, 张树才. 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察[J]. 中国肺癌杂志, 2015, 18:734-739.]
[17] Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies[J]. J Clin Oncol, 2001, 19:3267-3279.
[18] Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors:results of a phase Ⅰ trial[J]. J Clin Oncol, 2002, 20:2240-2250.
[19] Xi Li, Li Zhang, Da Jiang, Yan Wang, Aimin Zang, Cuimin Ding, Min Zhao, Wuyun Su, Yan Zhang, Diansheng Zhong, Jin Wu, Cuiying Zhang, Guangyu An, Xingsheng Hu, Gang Cheng, Huaqing Wang, Yongqun Li, Xiaohui He, Junli Liu, Li Liang, Lieming Ding, Li Mao, Shucai Zhang. Routine-dose and high-dose icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 21-L858R mutation:the randomized, phase Ⅱ, INCREASE trial[J]. Clin Cancer Res, 2020, 26:3162-3171.
[20] Lee SH, Kong DS, Seol HJ, Nam DH, Lee JI. Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis[J]. J Neurooncol, 2011, 104:545-551.

Please choose a citation manager

Content to export